These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 26673676)

  • 1. Pulmonary Fibrosis Foundation Summit 2015.
    Furlow B
    Lancet Respir Med; 2016 Jan; 4(1):13. PubMed ID: 26673676
    [No Abstract]   [Full Text] [Related]  

  • 2. Hot off the breath: A big step forward for idiopathic pulmonary fibrosis.
    Ryerson CJ; Collard HR
    Thorax; 2014 Sep; 69(9):791-2. PubMed ID: 24996636
    [No Abstract]   [Full Text] [Related]  

  • 3. Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib.
    Karimi-Shah BA; Chowdhury BA
    N Engl J Med; 2015 Mar; 372(13):1189-91. PubMed ID: 25806913
    [No Abstract]   [Full Text] [Related]  

  • 4. Novel treatments for idiopathic pulmonary fibrosis.
    Spagnolo P
    Am J Med; 2015 May; 128(5):447-9. PubMed ID: 25613299
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical trial research in focus: why do so many clinical trials fail in IPF?
    Spagnolo P; Maher TM
    Lancet Respir Med; 2017 May; 5(5):372-374. PubMed ID: 28412184
    [No Abstract]   [Full Text] [Related]  

  • 6. Update in diffuse parenchymal lung disease, 2013.
    Rosas IO; Kaminski N
    Am J Respir Crit Care Med; 2015 Feb; 191(3):270-4. PubMed ID: 25635490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New guideline on treatment of idiopathic pulmonary fibrosis.
    Spagnolo P; Bonella F; Maher TM
    Lancet Respir Med; 2015 Sep; 3(9):e31-e32. PubMed ID: 26380887
    [No Abstract]   [Full Text] [Related]  

  • 8. Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions.
    Raghu G; Selman M
    Am J Respir Crit Care Med; 2015 Feb; 191(3):252-4. PubMed ID: 25635489
    [No Abstract]   [Full Text] [Related]  

  • 9. Therapeutic advances in idiopathic pulmonary fibrosis.
    George G; Vaid U; Summer R
    Clin Pharmacol Ther; 2016 Jan; 99(1):30-2. PubMed ID: 26502087
    [No Abstract]   [Full Text] [Related]  

  • 10. Two therapies now available for idiopathic pulmonary fibrosis.
    Morrow T
    Manag Care; 2014 Dec; 23(12):47-8. PubMed ID: 25939185
    [No Abstract]   [Full Text] [Related]  

  • 11. Regulatory watch: Surprise setback for lung fibrosis drug highlights trial challenges.
    Nat Rev Drug Discov; 2010 Jul; 9(7):506. PubMed ID: 20592735
    [No Abstract]   [Full Text] [Related]  

  • 12. Recommendations for perioperative management of new pharmacological antifibrotic therapy in idiopathic pulmonary fibrosis.
    González Larrocha O; Romero Rojano P; Ortega Mera U; Arízaga Maguregui A
    Rev Esp Anestesiol Reanim (Engl Ed); 2018 Mar; 65(3):178-179. PubMed ID: 29183632
    [No Abstract]   [Full Text] [Related]  

  • 13. [Idiopathic pulmonary fibrosis -- progress in sight].
    Kaarteenaho R; Hodgson U; Myllärniemi M
    Duodecim; 2011; 127(24):2639-45. PubMed ID: 22320106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of Idiopathic Pulmonary Fibrosis Clinical Trials in the Era of Approved Therapies.
    Kaner RJ; Bajwa EK; El-Amine M; Gorina E; Gupta R; Lazarus HM; Luckhardt TR; Mouded M; Posada K; Richeldi L; Stauffer J; Tutuncu A; Martinez FJ
    Am J Respir Crit Care Med; 2019 Jul; 200(2):133-139. PubMed ID: 30985215
    [No Abstract]   [Full Text] [Related]  

  • 15. [Antifibrotic treatment].
    von der Beck D; Löh B; Drakopanagiotakis F; Markart P; Günther A
    Dtsch Med Wochenschr; 2014 Dec; 139(49):2523-5. PubMed ID: 25423462
    [No Abstract]   [Full Text] [Related]  

  • 16. [The Latest Information on Respiratory Disease Management. Topics: III. New Treatment of Idiopathic Pulmonary Fibrosis].
    Kashiwada T; Azuma A
    Nihon Naika Gakkai Zasshi; 2016 Jun; 105(6):970-6. PubMed ID: 30168687
    [No Abstract]   [Full Text] [Related]  

  • 17. Optimal treatment for idiopathic pulmonary fibrosis.
    Maher TM; Wells AU
    Thorax; 2008 Dec; 63(12):1120-1; author reply 1121. PubMed ID: 19020278
    [No Abstract]   [Full Text] [Related]  

  • 18. Update in Interstitial Lung Disease 2014.
    Belloli EA; Martinez FJ; Flaherty KR
    Am J Respir Crit Care Med; 2015 Sep; 192(5):538-43. PubMed ID: 26561676
    [No Abstract]   [Full Text] [Related]  

  • 19. The questionable efficacy of pirfenidone in IPF.
    Mathai SC; Polito AJ
    Am J Respir Crit Care Med; 2005 Nov; 172(9):1228. PubMed ID: 16249323
    [No Abstract]   [Full Text] [Related]  

  • 20. Idiopathic pulmonary fibrosis: the turning point is now!
    Funke M; Geiser T
    Swiss Med Wkly; 2015; 145():w14139. PubMed ID: 26024356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.